VSTx A New Generation of Indication-Level Drug Usage Insight
Specialist Analysis & Reporting on UK Prescribing of High-Cost Drugs
Improve your business intelligence decisions through the application of leading-edge data containing new levels of detail
Speak to us today to access
VSTx reports
Dummy data: for illustrative purposes only.
| REPORTING | FORECASTING | OPTIMISATION | |
|---|---|---|---|
| Indication-Level Drug Usage Reports own & competitors |
Launch Forecasting new indications &/or biosimilars |
Customer Segmentation, Targeting & Resource Allocation | Competitor Channel Mix Analysis |
| Launch Tracking new indications &/or biosimilars |
VPAG Tracking | Competitor Clinical Trial Analysis | |
| Discontinuation Rate Analysis weight-based |
|||
| Total Drug Usage Split by Indication |
NHSE Pricing Analysis | Commissioner Perspective | |
| REPORTING |
|---|
| Indication-Level Drug Usage Reports own & competitors |
| Launch Tracking new indications &/or biosimilars |
| Total Drug Usage Split by Indication |
| FORECASTING |
| Launch Forecasting new indications &/or biosimilars |
| Discontinuation Rate Analysis weight-based |
| OPTIMISATION |
| Customer Segmentation, Targeting & Resource Allocation |
| Competitor Channel Mix Analysis |
| VPAG Tracking |
| Competitor Clinical Trial Analysis |
| NHSE Pricing Analysis |
| Commissioner Perspective |
VSTx is available for use across a range of business intelligence needs
How can indication-level prescribing data help you? Help us understand the data you need and utilisations that interest you most, and we’ll get back in touch to start the conversation…
Speak to us today to
access VSTx reports
Start a conversation with Verpora to discover how VSTx can help you overcome data challenges and develop a partnership that meets your prescribing data needs.
Contact Wanda today to arrange an opportunity to learn more about the methodology and NHS data sources that power VSTx.
Wanda Lesowiec
VP Commercial Accounts
